Newsroom

LONDRES--(BUSINESS WIRE)--A Experian, empresa global de dados e tecnologia, e a ServiceNow (NYSE: NOW), torre de controle de IA para a reinvenção dos negócios, anunciam hoje uma parceria global plurianual que aproveita o poder de agentes de IA autônomos em todas as plataformas. A parceria ajudará as empresas a tomarem decisões mais rápidas e inteligentes em escala. Por meio dessa parceria, os agentes de IA autônomos podem adquirir a capacidade de agir com mais rapidez e de maneira mais consiste...

LONDRES--(BUSINESS WIRE)--Experian, la empresa global de datos y tecnología, y ServiceNow (NYSE: NOW), la torre de control de IA para la reinvención empresarial, presentan hoy una nueva asociación global plurianual que aprovecha el poder de los agentes autónomos de IA en todas las plataformas. El objetivo de esta alianza es ayudar a las empresas a tomar decisiones más rápidas e inteligentes a gran escala. A través de esta asociación, los agentes autónomos de IA pueden adquirir la capacidad de a...

CONSHOHOCKEN, Pennsylvania--(BUSINESS WIRE)--Boomi™, das Datenaktivierungsunternehmen für KI, gab heute eine Ausweitung seiner Partnerschaft mit ServiceNow, dem KI-Kontrollturm für die Neugestaltung von Unternehmen, bekannt, um erweiterte Datenaktivierungsfunktionen bereitzustellen, die in ServiceNow Workflow Data Fabric integriert sind. Im Rahmen dieser Zusammenarbeit wird Boomi als Launch-Partner für das „ServiceNow Workflow Data Network Passport Program“ fungieren und es Kunden erleichtern,...

LONDON--(BUSINESS WIRE)--  Re: ORBITA FUNDING 2023-1 PLC GBP 39,923,000.00 MATURING: 22-Oct-2030 ISIN: XS2699151291 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 22-Apr-2026 TO 22-May-2026 HAS BEEN FIXED AT 5.64 PCT DAY BASIS: ACTUAL/365(FIX) INTEREST PAYABLE VALUE 22-May-2026 WILL AMOUNT TO: GBP 184,913.49 PER GBP 39,923,000.00 DENOMINATION  ...

LONDON--(BUSINESS WIRE)--  Re: ORBITA FUNDING 2023-1 PLC GBP 32,664,000.00 MATURING: 22-Oct-2030 ISIN: XS2699151457 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 22-Apr-2026 TO 22-May-2026 HAS BEEN FIXED AT 6.54 PCT DAY BASIS: ACTUAL/365(FIX) INTEREST PAYABLE VALUE 22-May-2026 WILL AMOUNT TO: GBP 175,454.00 PER GBP 32,664,000.00 DENOMINATION  ...

LONDRA--(BUSINESS WIRE)--Experian, azienda globale specializzata in dati e tecnologia, e ServiceNow (NYSE: NOW), la piattaforma di controllo basata sull'AI dedicata alla trasformazione aziendale, oggi annuncia una nuova collaborazione mondiale pluriennale che sfrutta la potenza degli agenti AI autonomi su diverse piattaforme per aiutare le aziende a rendere più intelligenti e a velocizzare su larga scala i processi decisionali. Grazie a questa partnership, gli agenti AI autonomi potranno acquis...

LONDEN--(BUSINESS WIRE)--Experian, het internationale data- en technologiebedrijf, en ServiceNow (NYSE: NOW), de AI-controletoren om business opnieuw uit te vinden, onthulden vandaag een nieuw meerjarig globaal partnerschap dat de kracht van autonome AI agents in diverse platformen inzet im bedrijven te helpen sneller intelligentere beslissingen op schaal te nemen. Via dit partnerschap kunnen autonome AI agents het vermogen krijgen om sneller en consistenter te handelen, te beginnen met het aan...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) and Tecentriq Hybreza® (atezolizumab and hyaluronidase-tqjs) as an adjuvant treatment for adult patients with muscle-invasive bladder cancer (MIBC) who have circulating tumor DNA molecular residual disease (ctDNA MRD) after cystectomy, as identified by Natera’s Signatera™ CDx per...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved Signatera CDx as a companion diagnostic (CDx) for use with adjuvant atezolizumab (Tecentriq®) immunotherapy in MIBC. This is the first companion diagnostic approval in the field of blood-based MRD. It is a significant milestone in the industry-wide shift toward personalized, MRD-guided cancer care, in...

LONDON--(BUSINESS WIRE)--  Re: Lloyds Bank PLC USD 20,000,000.00 MATURING: 22-Nov-2028 ISIN: XS2723557620 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 23-Feb-2026 TO 22-May-2026 HAS BEEN FIXED AT 4.73 PCT DAY BASIS: ACTUAL/360 INTEREST PAYABLE VALUE 22-May-2026 WILL AMOUNT TO: USD 2,312.57 PER USD 200,000.00 DENOMINATION  ...